Verrica Pharmaceuticals Inc. Increase (Decrease) in Deferred Revenue
Verrica Pharmaceuticals Inc. (VRCA) reported Increase (Decrease) in Deferred Revenue of $481.00 thousand for the 6-month period ending 2025-06-30, per its 10-Q filed 2025-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2025-08-12
- Verrica Pharmaceuticals Inc. increase (decrease) in deferred revenue for the quarter ending 2022-12-31 was $0.00.
- Verrica Pharmaceuticals Inc. increase (decrease) in deferred revenue for the quarter ending 2022-09-30 was $0.00.
- Verrica Pharmaceuticals Inc. increase (decrease) in deferred revenue for the quarter ending 2022-06-30 was $0.00.
- Verrica Pharmaceuticals Inc. increase (decrease) in deferred revenue for the quarter ending 2022-03-31 was $0.00.
- Verrica Pharmaceuticals Inc. increase (decrease) in deferred revenue for fiscal 2022 was $0.00.
- Verrica Pharmaceuticals Inc. increase (decrease) in deferred revenue for fiscal 2021 was -$500.00K, a 200.00% decline from fiscal 2020.
- Verrica Pharmaceuticals Inc. increase (decrease) in deferred revenue for fiscal 2020 was $500.00K.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|
| 2025-06-30 | $481.00K 10-Q · filed 2025-08-12 | |||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-12 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $0.00 derived: sum of 2 quarters · filed 2023-03-06 | $0.00 derived: sum of 3 quarters · filed 2023-03-06 | $0.00 10-K · filed 2023-03-06 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $0.00 derived: sum of 2 quarters · filed 2022-11-07 | $0.00 10-Q · filed 2022-11-07 | $0.00 derived: sum of 4 quarters · filed 2023-03-06 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $0.00 10-Q · filed 2022-08-11 | $0.00 derived: sum of 3 quarters · filed 2023-03-06 | $0.00 derived: sum of 4 quarters · filed 2023-03-06 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-09 | $0.00 derived: sum of 2 quarters · filed 2023-03-06 | $0.00 derived: sum of 3 quarters · filed 2023-03-06 | $0.00 derived: sum of 4 quarters · filed 2023-03-06 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $0.00 derived: sum of 2 quarters · filed 2023-03-06 | $0.00 derived: sum of 3 quarters · filed 2023-03-06 | -$500.00K 10-K · filed 2023-03-06 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $0.00 derived: sum of 2 quarters · filed 2022-11-07 | -$500.00K 10-Q · filed 2022-11-07 | -$500.00K derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$500.00K 10-Q · filed 2022-08-11 | -$500.00K derived: sum of 3 quarters · filed 2022-08-11 | |
| 2021-03-31 | -$500.00K 10-Q · filed 2022-05-09 | -$500.00K derived: sum of 2 quarters · filed 2022-05-09 | ||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-02 | $500.00K 10-K · filed 2022-03-02 | ||
| 2020-09-30 | $500.00K 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |